8-K 1 f8kjan2002.txt FORM 8-K - ITEM 5. OTHER EVENTS SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2002 MIRAVANT MEDICAL TECHNOLOGIES (Exact name of registrant as specified in its charter) Delaware 0-25544 77-0222872 (State or other jurisdiction of (Commission (IRS Employer Identification incorporation) File Number) Number) 336 Bollay Drive Santa Barbara, California 93117 (Address of principal executive offices) (Zip Code) ------------------------------------------------------------------------ Registrant's telephone number, including area code: (805) 685-9880 N/A (Former Name or Former Address, if Changed Since Last Report) ITEM 5. Other Events On January 13, 2002 we issued a press release announcing the results of our Phase III clinical trials of SnET2, or tin ethyl etiopurpurin, an investigational drug developed for the wet form of age-related macular degeneration, or wet AMD. The top line results of the trials indicate that SnET2 did not meet the primary efficacy endpoint in this study population. The press release is attached as Exhibit 99 to this Form 8-K and is incorporated in this report in its entirety. Item 7. Exhibits Exhibit Number Exhibit Exhibit 99 Miravant Medical Technologies January 13, 2002 Press Release. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRAVANT MEDICAL TECHNOLOGIES By: /s/ John M. Philpott ----------------------------------- Name: John M. Philpott Title: Chief Financial Officer Date: January 16, 2002 Exhibit Number Exhibit Exhibit 99 Miravant Medical Technologies January 13, 2002 Press Release.